Clinical Research Advantage, Inc.

Council Bluffs, Iowa 51503

0 studies enrolling now · 4 studies all time

What they study most

Cardiovascular Disease, Healthy, Meningococcal Infection

Studies at this site

• Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early